

Special Issue

Advances in Angiogenesis, Inflammation, and Oxidative Stress in Inflammatory Bowel Diseases

Message from the Guest Editors

Research over the last few decades has led to the use of biological therapy with human monoclonal antibodies, which has enabled the improved regulation of both the cellular immune response and inflammation of the intestinal mucosa, leading to clinical remission and endoscopic healing. However, there are patients in whom mucosal healing is not observed or alters the natural history of their inflammatory bowel disease. In light of these observations, in this Special Issue, we will collect important studies (original research or review articles) regarding the evaluation of angiogenic, inflammatory, and oxidative stress in patients with IBD. Studies investigating the hypothesis that angiogenesis and oxidative stress contribute significantly to mucosal inflammation in IBD are also welcome. Since symptoms are often subjective, and invasive procedures are often a burden for the patient, studying the interrelation between angiogenic factors, inflammatory markers, and oxidative stress factors will enable an objective measurement of disease activity.

Guest Editors

Dr. Mihail Virgil Boldeanu

Department of Immunology, University of Medicine and Pharmacy,
200349 Craiova, Romania

Prof. Dr. Dan Ionuț Gheonea

Department of Gastroenterology, University of Medicine and Pharmacy
of Craiova, Craiova, Romania

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/195432

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).